Almotriptan
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Almotriptan: 5-HT1B/1D receptor agonist (triptan) → atrophoderma vermiculata
One-Sentence Summary
Almotriptan is a triptan-class medicine that acts on serotonin receptors. The TxGNN model predicts it may be relevant to atrophoderma vermiculata, but no clinical trials and no publications were found to support this direction, so it remains a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | atrophoderma vermiculata |
| TxGNN Prediction Score | 0.9977 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 6 of 6) |
| Number of DINs | 6 (marketed: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Almotriptan belongs to the triptan class, which acts as an agonist at 5-HT1B/1D serotonin receptors.
Atrophoderma vermiculata is a rare follicular keratotic skin disorder with atrophic, inflammatory changes on the cheeks. No plausible mechanistic link was identified between 5-HT1B/1D agonism and this condition. The high score appears to reflect shared neighbourhood patterns in the model rather than biological support, so the prediction should be treated with caution.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
- Contraindications flagged in the model’s data (not label text): hypertension, coronary artery disease, myocardial infarction, myocardial ischemia, Prinzmetal angina, stroke and transient ischemic attack, cerebrovascular disorder, peripheral vascular disease, Raynaud disease, liver disease, diabetes, obesity, serotonin syndrome, and familial or sporadic hemiplegic migraine. These should be verified against the product label.
- Drug Interactions: 56 interactions were recorded. Major-level ones include the 5-HT3 antagonists ondansetron, granisetron, dolasetron and palonosetron, and the serotonergic agents fenfluramine, dexfenfluramine, lorcaserin and sibutramine. Moderate-level ones include aprepitant, clarithromycin and morphine.
Label-based warnings were not available in the compiled data; please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. No clinical trials or publications address this disease, and no plausible mechanistic link was identified. Evidence level is L5.
To proceed, the following is needed:
- Any preclinical or clinical evidence directly studying almotriptan, or serotonin receptor pathways, in atrophoderma vermiculata
- Mechanism-of-action data and a biological rationale for skin involvement
- Health Canada package insert warnings and contraindications for the safety screen
- Assessment of route compatibility (oral formulation vs. a likely dermatological need)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.